VANGL2 and breast cancer: Loss of Vangl2 significantly reduces RhoA activity in leader cells, but has no impact on follower cell RhoA activity, suggesting that a Vangl2-RhoA signaling axis may be specific to leader cell biology and responsible for the protrusive leading-edge phenotype observed in Vangl overexpressing breast cancer cells.